Masato Asanuma

Prof. Masato Asanuma

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
MAMasato Asanuma
Masato Asanuma
IMIkuko Miyazaki
Ikuko Miyazaki
NONorio Ogawa
Norio Ogawa

7 December 2020 in Cells
Verified
Journal Article
Open access
PDF file
Ikuko MiyazakiIkuko Miyazaki
Ikuko Miyazaki
MAMasato Asanuma
Masato Asanuma
Parkinson’s disease (PD) is the second most common neurodegenerative disease. PD patients exhibit motor symptoms such as akinesia/bradykinesia, tremor, rigidity, and postural instability due to a loss of nigrostriatal dopaminergic neurons. Although the pathogenesis in sporadic PD remains unknown, there is a consensus on the involvement of non-neuronal cells in the progression of PD pathology. Astrocytes are the most numerous glial cells in the central nervous system. Normally, astrocytes protect neurons by releasing neurotrophic factors, producing antioxidants, and disposing of neuronal waste products. However, in pathological situations, astrocytes are known to produce inflammatory cytokines. In addition, various studies have reported that astrocyte dysfunction also leads to neurodegeneration in PD. In this article, we summarize the interaction of astrocytes and dopaminergic neurons, review the pathogenic role of astrocytes in PD, and discuss therapeutic strategies for the prevention of dopaminergic neurodegeneration. This review highlights neuron-astrocyte interaction as a target for the development of disease-modifying drugs for PD in the future.

15 March 2001 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
MAMasato Asanuma
Masato Asanuma
SNSakiko Nishibayashi‐Asanuma
Sakiko Nishibayashi‐Asanuma
IMIkuko Miyazaki
Ikuko Miyazaki
MKMasahiro Kohno
Masahiro Kohno
NONorio Ogawa
Norio Ogawa
Recently, it has been reported that inflammatory processes are associated with the pathophysiology of Alzheimer's disease and that treatment of non‐steroidal anti‐inflammatory drugs reduce the risk for Alzheimer's disease. In the present study, we examined nitric oxide radical quenching activity of non‐steroidal anti‐inflammatory drugs and steroidal drugs using our established direct in vitro nitric oxide radical detecting system by electron spin resonance spectrometry. The non‐steroidal anti‐inflammatory drugs, aspirin, mefenamic acid, indomethacin and ketoprofen directly and dose‐dependently scavenged generated nitric oxide radicals. In experiments of nitric oxide radical donor, NOC18‐induced neuronal damage, these four non‐steroidal drugs significantly prevented the NOC18‐induced reduction of cell viability and apoptotic nuclear changes in neuronal cells without affecting the induction of inducible nitric oxide synthase‐like immunoreactivity. However, ibuprofen, naproxen or steroidal drugs, which had less or no scavenging effects in vitro, showed almost no protective effects against NOC18‐induced cell toxicity. These results suggest that the protective effects of the former four non‐steroidal anti‐inflammatory drugs against apoptosis might be mainly due to their direct nitric oxide radical scavenging activities in neuronal cells. These direct NO· quenching activities represent novel effects of non‐steroidal anti‐inflammatory drugs. Our findings identified novel pharmacological mechanisms of these drugs to exert not only their anti‐inflammatory, analgesic, antipyretic activities but also neuroprotective activities against neurodegeneration.

Verified
Journal Article
Open access
PDF file
Ikuko MiyazakiIkuko Miyazaki
Ikuko Miyazaki
NINami Isooka
Nami Isooka
FIFuminori Imafuku
Fuminori Imafuku
JSJin Sun
Jin Sun
RKRyo Kikuoka
Ryo Kikuoka
MAMasato Asanuma
Masato Asanuma
Epidemiological studies demonstrated that pesticide exposure, such as rotenone and paraquat, increases the risk of Parkinson’s disease (PD). Chronic systemic exposure to rotenone, a mitochondrial complex I inhibitor, could reproduce many features of PD. However, the adoption of the models is limiting because of variability in animal sensitivity and the inability of other investigators to consistently reproduce the PD neuropathology. In addition, most of rotenone models were produced in rats. Here, we tried to establish a high-reproducible rotenone model using C57BL/6J mice. The rotenone mouse model was produced by chronic systemic exposure to a low dose of rotenone (2.5 mg/kg/day) for 4 weeks by subcutaneous implantation of rotenone-filled osmotic mini pump. The rotenone-treated mice exhibited motor deficits assessed by open field, rotarod and cylinder test and gastrointestinal dysfunction. Rotenone treatment decreased the number of dopaminergic neuronal cells in the substantia nigra pars compacta (SNpc) and lesioned nerve terminal in the striatum. In addition, we observed significant reduction of cholinergic neurons in the dorsal motor nucleus of the vagus (DMV) and the intestinal myenteric plexus. Moreover, α-synuclein was accumulated in neuronal soma in the SNpc, DMV and intestinal myenteric plexus in rotenone-treated mice. These data suggest that the low-dose rotenone mouse model could reproduce behavioral and central and peripheral neurodegenerative features of PD and be a useful model for investigation of PD pathogenesis.

1 November 2003 in Neuroscience Letters
Verified
Journal Article
Closed access
MAMasato Asanuma
Masato Asanuma
TTTakeshi Tsuji
Takeshi Tsuji
IMIkuko Miyazaki
Ikuko Miyazaki
KMKo Miyoshi
Ko Miyoshi
NONorio Ogawa
Norio Ogawa

Verified
Journal Article
Open access
PDF file
MAMasato Asanuma
Masato Asanuma
Ikuko MiyazakiIkuko Miyazaki
Ikuko Miyazaki
Glutathione (GSH) is the most abundant intrinsic antioxidant in the central nervous system, and its substrate cysteine readily becomes the oxidized dimeric cystine. Since neurons lack a cystine transport system, neuronal GSH synthesis depends on cystine uptake via the cystine/glutamate exchange transporter (xCT), GSH synthesis, and release in/from surrounding astrocytes. Transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2), a detoxifying master transcription factor, is expressed mainly in astrocytes and activates the gene expression of various phase II drug-metabolizing enzymes or antioxidants including GSH-related molecules and metallothionein by binding to the antioxidant response element (ARE) of these genes. Accumulating evidence has shown the involvement of dysfunction of antioxidative molecules including GSH and its related molecules in the pathogenesis of Parkinson’s disease (PD) or parkinsonian models. Furthermore, we found several agents targeting GSH synthesis in the astrocytes that protect nigrostriatal dopaminergic neuronal loss in PD models. In this article, the neuroprotective effects of supplementation and enhancement of GSH and its related molecules in PD pathology are reviewed, along with introducing new experimental findings, especially targeting of the xCT-GSH synthetic system and Nrf2–ARE pathway in astrocytes.